Continued Investigations are Pertinent for FDA Approvals in the Treatment of Patients With EGFR-mutated NSCLC

Jason Porter, MD, highlights the implications of recent data to emerge following the use of EGFR TKIs in the adjuvant setting, the importance of the potential upcoming FDA approval of osimertinib with chemotherapy in EGFR-positive non–small cell lung cancer, and more.

Related Keywords

Tennessee ,United States ,Memphis ,Wadet Iams ,Danielv Wakefield ,Erina Gillaspie ,Nagla Abdel Karim ,Jason Porter ,Vanderbilt Ingram Cancer Center ,Research Institute In Memphis ,University Of Virginia ,Institutional Perspectives ,Lung Cancer Disease Research Group ,West Cancer Center ,Research Institute ,Egfr Tkis ,Nsclc ,Osimertinib ,Adaura Trial ,Institutional Perspectives In Cancer ,Egfr Mutations ,Non Small Cell Lung Cancer ,